Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Co's existing focus is on the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus. Co.'s product candidate for the treatment of COVID-19 is bemnifosbuvir. For the treatment of chronic HCV infection, Co. is developing a combination of bemnifosbuvir and ruzasvir, an investigational nonstructural protein 5A inhibitor. Co. is developing AT-752, an oral, purine nucleotide prodrug for the treatment of dengue. We show 13 historical shares outstanding datapoints in our AVIR shares outstanding history coverage, used to compute AVIR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AVIR market cap history over the course of time is important for investors
interested in comparing AVIR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AVIR versus a peer is one thing; comparing
AVIR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AVIR can fluctuate over the course of history.
With this page we aim to empower investors researching AVIR by allowing them to research the AVIR market cap history. |
Free AVIR Email Alerts:
Video: The Importance of Market Cap
